Choose an application

• Reference Manager
• EndNote
• RefWorks (Direct export to RefWorks)

Omics technologies such as proteomics, genomics, and metabolomics are widely applied for the identification and characterization of new molecular signatures. However, molecular profiling that makes it possible to understand neurodegenerative diseases has been relatively insufficient. Brain diseases such as neurodegenerative diseases and emotional disorders need integrative understanding which draws on a more reliable hypothesis for pathology, which can be accomplished via in-depth study of molecular information. Recently, multi-omics technologies have been eagerly applied to a diverse range of diseases. As this includes multiple molecular profiling, metadata, and Big Data processing with informatics and computer science, it is possible to provide new macroscopic and microscopic insights in order to better understand diseases. This Special Issue will introduce recent technological advances in multi-omics and the application of omics technology to brain diseases.

Research & information: general --- schizophrenia --- abnormal behavior gene set --- region --- differentially expressed genes --- de novo mutation --- copy number variant --- SIDS --- newborn infant --- genetic polymorphism --- neurotransmitter --- epigenetics --- epigenome --- zinc finger domain --- zinc finger motif --- zinc finger proteins --- zinc metalloproteins --- flow infusion analysis --- chloride adducts --- ceramides --- sphingolipids --- glycerophosphocholines --- human brain --- NAD+ --- nicotinamide --- ageing --- plasma --- biomarker --- CNV --- PPI --- spatiotemporal network --- chromosome 22q11.21 --- DGCR8 --- Orthosiphon stamineus --- plant-derived proteins --- neuroprotective --- SH-SY5Y cell model --- hydrogen peroxide --- CSF --- miRNAs --- neurological diseases --- OpenArray --- morphine --- withdrawal --- brain --- proteomics --- synaptic plasticity --- Alzheimer's disease --- microfluidics --- lab-on-chip --- 3D culture --- organ-on-chip --- schizophrenia --- abnormal behavior gene set --- region --- differentially expressed genes --- de novo mutation --- copy number variant --- SIDS --- newborn infant --- genetic polymorphism --- neurotransmitter --- epigenetics --- epigenome --- zinc finger domain --- zinc finger motif --- zinc finger proteins --- zinc metalloproteins --- flow infusion analysis --- chloride adducts --- ceramides --- sphingolipids --- glycerophosphocholines --- human brain --- NAD+ --- nicotinamide --- ageing --- plasma --- biomarker --- CNV --- PPI --- spatiotemporal network --- chromosome 22q11.21 --- DGCR8 --- Orthosiphon stamineus --- plant-derived proteins --- neuroprotective --- SH-SY5Y cell model --- hydrogen peroxide --- CSF --- miRNAs --- neurological diseases --- OpenArray --- morphine --- withdrawal --- brain --- proteomics --- synaptic plasticity --- Alzheimer's disease --- microfluidics --- lab-on-chip --- 3D culture --- organ-on-chip

Choose an application

• Reference Manager
• EndNote
• RefWorks (Direct export to RefWorks)

Rare diseases, or orphan diseases, are those that individually affect a small number of patients, but taken together affect over 300 million people worldwide. They are characterized by their etiological, diagnostic and evolutionary complexity, important morbi-mortality, with high levels of disability that entail and hinder the development of a normal vital subject, not only in those who suffer from them, but also their families; therefore, a comprehensive social health approach is necessary to address this problem.About 80% of rare diseases have a genetic origin, mainly monogenic; thus, genetic testing is mandatory for the confirmation of clinical diagnostics and to ensure correct genetic counseling. Next-generation sequencing (NGS) has enabled a revolution in genetic diseases, specially in rare diseases. However, their complexity makes diagnoses difficult even with the advent of NGS.In this Special Issue, we present several examples of the complexity of genetic diagnosis for most of these diseases and the consequences that genetic testing implies for genetic counseling. There are examples of the genetic heterogeneity of hearing loss, some metabolic and lisosomal disorders, ataxia, Prader–Willi syndrome, and three comprehensive reviews on syndromic retinal dystrophies, the complexity of the molecular diagnosis of neuromuscular disorders, and the value of genetic counseling before and after a genetic test.

Medicine --- retina --- inherited retinal diseases --- syndrome --- Turner syndrome --- mosaicism --- ring chromosomes --- growth hormone deficiency --- pituitary microadenoma --- clinical genetics --- early onset ataxia --- dystonia --- neurodevelopment --- network analysis --- bioinformatics --- ataxia --- phenotype --- child --- NGS --- next generation sequencing --- inborn errors of metabolism --- lysosomal disorders --- neuromuscular disease --- genetic testing --- whole exome sequencing --- Prader-Willi syndrome --- imprinting disorder --- recombinant human growth hormone --- insulin-like growth factor 1 --- HMGLD --- HMGCL --- HMG-CoA lyase deficiency --- inherited metabolic diseases --- familial hearing loss --- multiple diagnoses --- non-syndromic hearing loss --- ACTG1 --- MYH9 --- genetic counselling --- rare diseases --- professional recognition --- hearing loss --- genetic diagnosis --- SLC26A4 --- DFNB4 --- Tuvinians --- Altaians --- Southern Siberia --- Russia --- GSDME --- DFNA5 --- single-exon CNV --- retina --- inherited retinal diseases --- syndrome --- Turner syndrome --- mosaicism --- ring chromosomes --- growth hormone deficiency --- pituitary microadenoma --- clinical genetics --- early onset ataxia --- dystonia --- neurodevelopment --- network analysis --- bioinformatics --- ataxia --- phenotype --- child --- NGS --- next generation sequencing --- inborn errors of metabolism --- lysosomal disorders --- neuromuscular disease --- genetic testing --- whole exome sequencing --- Prader-Willi syndrome --- imprinting disorder --- recombinant human growth hormone --- insulin-like growth factor 1 --- HMGLD --- HMGCL --- HMG-CoA lyase deficiency --- inherited metabolic diseases --- familial hearing loss --- multiple diagnoses --- non-syndromic hearing loss --- ACTG1 --- MYH9 --- genetic counselling --- rare diseases --- professional recognition --- hearing loss --- genetic diagnosis --- SLC26A4 --- DFNB4 --- Tuvinians --- Altaians --- Southern Siberia --- Russia --- GSDME --- DFNA5 --- single-exon CNV

Choose an application

• Reference Manager
• EndNote
• RefWorks (Direct export to RefWorks)

Polypharmacy is a necessary and important aspect of drug treatment; however, it becomes a challenge when the medication risks outweigh the benefits for an individual patient. Drug–drug interactions and the introduction of prescribing cascades are common features of polypharmacy, which can lead to ineffectiveness and increased risk of adverse drug reactions (ADR). Genes encoding CYP450 isozymes and other drug-related biomarkers have attracted considerable attention as targets for pharmacogenetic (PGx) testing due to their impact on drug metabolism and response. This Special Issue is devoted to explore the status and initiatives taken to circumvent ineffectiveness and to improve medication safety for polypharmacy patients. Specific areas include drug–drug interactions and consequences thereof in therapeutic management, including PK- and PD-profiling; the application of PGx-based guidance and/or decision tools for drug–gene and drug–drug gene interactions; medication reviews; development and application of deprescribing tools; and drivers and barriers to overcome for successful implementation in the healthcare system.

Medicine --- Pharmaceutical industries --- acute kidney injury --- early biomarker --- plasma neutrophil gelatinase-associated lipocalin --- soluble urokinase plasminogen activator receptor --- medication optimization --- older patients --- emergency department --- multimorbidity --- polypharmacy --- potentially inappropriate medication use --- older adults --- prevalence --- determinants --- chronic --- outpatient --- 2019 Beers criteria --- Ethiopia --- pharmacogenomics --- persons with diabetes --- drug–drug interactions --- drug–gene interactions --- cytochrome P450 --- SLCO1B1 --- drug interaction checkers --- adverse drug reactions --- pharmacogenetics --- personalized medicine --- phenprocoumon --- DOACs --- bleeding --- thromboembolism --- HLA --- drug hypersensitivity --- abacavir --- allopurinol --- flucloxacillin --- antiepileptic drugs --- cost-effectiveness --- shared medication record --- medication reconciliation --- drug information service --- hospital pharmacy service --- electronic prescribing --- electronic medical record --- clinical pharmacist --- CYP2D6 --- CYP2D7P --- CYP2D8P --- copy number variation --- CNV --- genotyping --- 5’nuclease assay --- HRM --- high resolution melting --- drug metabolization --- extracellular vesicles --- exosomes --- microvesicles --- pharmacogene expression --- medication review --- deprescriptions --- quality of life --- aged --- aged, 80 and over --- nursing homes --- deprescribing --- medication-based risk score --- health outcomes --- cytochromes --- CYP1A2 --- adverse drug reaction --- antipsychotics --- olanzapine --- clozapine --- loxapine --- children --- youth --- digital decision-support --- health services research --- general practice --- process evaluation --- antidepressants --- utility --- population-based --- appropriateness --- medication adherence --- digital health --- acute kidney injury --- early biomarker --- plasma neutrophil gelatinase-associated lipocalin --- soluble urokinase plasminogen activator receptor --- medication optimization --- older patients --- emergency department --- multimorbidity --- polypharmacy --- potentially inappropriate medication use --- older adults --- prevalence --- determinants --- chronic --- outpatient --- 2019 Beers criteria --- Ethiopia --- pharmacogenomics --- persons with diabetes --- drug–drug interactions --- drug–gene interactions --- cytochrome P450 --- SLCO1B1 --- drug interaction checkers --- adverse drug reactions --- pharmacogenetics --- personalized medicine --- phenprocoumon --- DOACs --- bleeding --- thromboembolism --- HLA --- drug hypersensitivity --- abacavir --- allopurinol --- flucloxacillin --- antiepileptic drugs --- cost-effectiveness --- shared medication record --- medication reconciliation --- drug information service --- hospital pharmacy service --- electronic prescribing --- electronic medical record --- clinical pharmacist --- CYP2D6 --- CYP2D7P --- CYP2D8P --- copy number variation --- CNV --- genotyping --- 5’nuclease assay --- HRM --- high resolution melting --- drug metabolization --- extracellular vesicles --- exosomes --- microvesicles --- pharmacogene expression --- medication review --- deprescriptions --- quality of life --- aged --- aged, 80 and over --- nursing homes --- deprescribing --- medication-based risk score --- health outcomes --- cytochromes --- CYP1A2 --- adverse drug reaction --- antipsychotics --- olanzapine --- clozapine --- loxapine --- children --- youth --- digital decision-support --- health services research --- general practice --- process evaluation --- antidepressants --- utility --- population-based --- appropriateness --- medication adherence --- digital health

Choose an application

• Reference Manager
• EndNote
• RefWorks (Direct export to RefWorks)

The book highlights important aspects of Molecular Psychiatry, including molecular mechanisms, animal models, biomarkers, advanced methods, drugs and antidepressant response, as well as genetics and epigenetics. Molecular mechanisms are a vital part of the search for the biological basis of psychiatric disorders, providing molecular hints that can later be tested as biomarkers or targets for drug development. Animal models represent a commonly used approach to aid in this bench-to-bed translation; the examples here are social defeat stress and the Roman High-Avoidance (RHA) and the Roman Low-Avoidance (RLA) rats. For biomarkers, psychiatric disorders pose a particular challenge due to the tissue specificity of many currently investigated biomarkers; i.e., not all blood-based measures directly represent changes in the brain. The Ebook includes five articles focused on the challenges of identifying clinically and biologically relevant biomarkers for psychiatric disorders. Scientific progress typically is fostered by the development of new methods. The application of machine learning methods for the proper analysis of Big Data and induced pluripotent stem cells are examples outlined in this Ebook. Furthermore, three articles are devoted to the understanding of the mechanisms of actions of existing drugs with the ultimate goal of identifying ways to predict treatment response in patients. Finally, three articles deepen the insight into the genetics and epigenetics of psychiatric disorders.

Medicine --- Mental health services --- cardiovascular disease --- cell adhesion molecules --- immunology --- inflammation --- nervous system --- schizophrenia --- bipolar disorder --- major depressive disorder --- DNA methylation --- response variability --- antipsychotics --- drug design --- multi-target drugs --- polypharmacology --- multi-task learning --- machine learning --- biomarker discovery --- psychiatry --- serotonin --- 5-HT 4 receptor --- 5-HT4R --- depression --- mood disorder --- expression --- Alzheimer's disease --- cognition --- Parkinson's disease --- forced swimming --- Roman rat lines --- stress --- hippocampus --- BDNF --- trkB --- PSA-NCAM --- western blot --- immunohistochemistry --- general cognitive function --- intelligence --- GWAS --- genetic correlation --- childhood-onset schizophrenia (COS) --- induced pluripotent stem cell (iPSC) --- copy number variation (CNV) --- early neurodevelopment --- neuronal differentiation --- synapse --- dendritic arborization --- miRNAs --- stress physiology --- cytoskeleton --- actin dynamics --- DRR1 --- TU3A --- FAM107A --- acid sphingomyelinase --- alcohol dependence --- liver enzymes --- sphingolipid metabolism --- withdrawal --- Hsp90 --- GR --- stress response --- steroid hormones --- molecular chaperones --- psychiatric disease --- circadian rhythms --- FKBP51 --- FKBP52 --- CyP40 --- PP5 --- DISC1 --- neurodevelopment --- CRMP-2 --- proteomics --- antidepressant treatment --- HPA axis --- gene expression --- FKBP5 --- sleep --- sleep EEG --- biomarkers --- antidepressants --- cordance --- gender --- sex difference --- antidepressant --- rapid-acting --- Ketamine --- endocrinology --- (2R,6R)-Hydroxynorketamine --- electroconvulsive therapy --- basic-helix-loop-helix --- brain --- coactivator --- glucocorticoids --- mineralocorticoid receptor knockout --- transcription biology --- dopaminergic gene polymorphisms --- affective temperament --- obesity --- alpha-synuclein --- SNCA --- major depression --- Hamilton Scale of Depression --- chemokines --- neuroinflammation --- social defeat --- Immune response --- T cells --- susceptibility --- resilience --- Treg cells --- Th17 cells --- behavior --- PPARγ --- cardiovascular disease --- cell adhesion molecules --- immunology --- inflammation --- nervous system --- schizophrenia --- bipolar disorder --- major depressive disorder --- DNA methylation --- response variability --- antipsychotics --- drug design --- multi-target drugs --- polypharmacology --- multi-task learning --- machine learning --- biomarker discovery --- psychiatry --- serotonin --- 5-HT 4 receptor --- 5-HT4R --- depression --- mood disorder --- expression --- Alzheimer's disease --- cognition --- Parkinson's disease --- forced swimming --- Roman rat lines --- stress --- hippocampus --- BDNF --- trkB --- PSA-NCAM --- western blot --- immunohistochemistry --- general cognitive function --- intelligence --- GWAS --- genetic correlation --- childhood-onset schizophrenia (COS) --- induced pluripotent stem cell (iPSC) --- copy number variation (CNV) --- early neurodevelopment --- neuronal differentiation --- synapse --- dendritic arborization --- miRNAs --- stress physiology --- cytoskeleton --- actin dynamics --- DRR1 --- TU3A --- FAM107A --- acid sphingomyelinase --- alcohol dependence --- liver enzymes --- sphingolipid metabolism --- withdrawal --- Hsp90 --- GR --- stress response --- steroid hormones --- molecular chaperones --- psychiatric disease --- circadian rhythms --- FKBP51 --- FKBP52 --- CyP40 --- PP5 --- DISC1 --- neurodevelopment --- CRMP-2 --- proteomics --- antidepressant treatment --- HPA axis --- gene expression --- FKBP5 --- sleep --- sleep EEG --- biomarkers --- antidepressants --- cordance --- gender --- sex difference --- antidepressant --- rapid-acting --- Ketamine --- endocrinology --- (2R,6R)-Hydroxynorketamine --- electroconvulsive therapy --- basic-helix-loop-helix --- brain --- coactivator --- glucocorticoids --- mineralocorticoid receptor knockout --- transcription biology --- dopaminergic gene polymorphisms --- affective temperament --- obesity --- alpha-synuclein --- SNCA --- major depression --- Hamilton Scale of Depression --- chemokines --- neuroinflammation --- social defeat --- Immune response --- T cells --- susceptibility --- resilience --- Treg cells --- Th17 cells --- behavior --- PPARγ

Choose an application

• Reference Manager
• EndNote
• RefWorks (Direct export to RefWorks)

In recent years, peptides have received increased interest from the pharmaceutical industry. The high potency, specificity, and safety profile are the main strengths of bioactive peptides as new and promising therapies that may fill the gap between small molecules and protein drugs. These positive attributes have renewed interest in the discovery, optimization, and development of peptides as pharmacological therapy. Among bioactive peptides, those released from food sources have acquired importance as nutraceutical and active components in functional foods because they possess regulatory functions that can lead to health benefits. This Special Issue covers a selection of recent research papers and reviews in the field of bioactive peptides. It covers all aspects of peptide research in relation to health promotion. In particular, it emphasizes current knowledge and research trends concerning bioactive peptides, including identification and quantification of peptides from new sources, methods for their production and purification, structure–function relationships, mechanisms of action, in vitro and in vivo assays for the evaluation of their bioactivity, physiological evidence to support health benefits, and peptide stability and bioavailability. Papers regarding the development of new drugs, functional foods, or nutraceuticals based on bioactive peptides were also considered.

Research & information: general --- Biology, life sciences --- antihypertensive peptides --- functional food --- food-derived --- fermentation --- Chlorella sorokiniana --- in silico --- BIOPEP-UWM database --- proteomics --- bioactive peptides --- nano liquid chromatography tandem mass spectrometry (nanoLC-nanoESI MS/MS) --- apolipoprotein E --- amyloid fibrils --- Alzheimer's disease --- Αβ oligomer --- amyloid --- Aβ peptide --- glioma --- platelets --- antiproliferative assay --- conjugation --- docetaxel --- doxorubicin --- extra domain B --- fibronectin --- Fmoc/tBu --- peptide-drug conjugate --- prostate cancer --- solid-phase synthesis --- targeting --- acrylamide --- enteric nervous system --- galanin --- pig --- stomach --- formyl peptide receptors --- ligands --- diseases --- polymicrobial biofilms --- intragenic antimicrobial peptide --- Hs02 --- Pseudomonas aeruginosa --- Staphylococcus aureus --- osteostatin --- arthritis --- inflammation --- immune response --- cartilage destruction --- bone erosion --- collagen --- hydrolysis --- enzyme --- molecular weight --- sheepskin --- NF-κB --- dry-cured pork ham --- angiotensin I converting enzyme --- endothelial dysfunction --- molecular blind docking --- Lactoferricin B (Lfcin B) --- Histatin-5 --- antimicrobial peptides (AMPs) --- antifungal activity --- proteome microarray --- synergy --- temporin --- MRSA --- antimicrobial peptide --- human keratinocytes --- pseudin-2 --- antisepsis, peptide antibiotics --- neurotensin --- asthma --- T cells --- In situ tetramer staining --- MHC tetramer --- antigen-specific --- confocal microscopy --- fresh tissue --- velvet antler --- alcalase hydrolysate --- antioxidant peptide --- protection ability --- oxidative stress --- Crassostrea angulata --- pidotimod --- CXCR3 --- monocyte --- migration --- PI3K/Akt pathway --- T cell --- immunomodulant --- host defense peptides --- membrane activity --- copper --- piscidins --- Clostridioides difficile --- prolactin-releasing peptide --- GPR10 --- RF-amide peptides --- food intake regulation --- energy expenditure --- neuroprotection --- signaling --- gender differences --- dyslipidemia --- obesity --- hyperglycemia --- pulmonary emphysema --- endothelial progenitor cells --- angiogenic precursor cells --- pegylated glucagon-like peptide 1 --- and endothelial regeneration --- miiuy croaker (Miichthys miiuy) --- swim bladder --- FPYLRH --- antioxidant activity --- cytoprotective effect --- antimicrobial peptides --- antimicrobial resistance --- AMP identification and design --- biosynthesis --- mode of action --- physico-chemical properties --- therapeutic potential --- insects --- Cecropins --- Cec-analogs --- MDR infectious diseases --- airway inflammation --- non-atopic asthma --- hybrid peptide --- pro-inflammatory cytokines --- sPLA2 --- MDA --- database --- proteolysis --- SMILES code --- foods --- nutrition --- chronic diseases --- nutraceuticals --- peptide vaccine --- immune checkpoint inhibitor --- humanized mouse --- cancer antigen --- immune suppression --- vasoactive intestinal peptide --- VPAC1 receptor --- VPAC2 receptor --- rheumatic diseases --- inflammatory bowel disease --- central nervous system diseases --- type 1 diabetes --- Sjögren's syndrome --- biomarkers --- human antimicrobial peptides --- defensins --- cathelicidins --- anti-inflammatory --- pro-inflammatory --- peptide --- combinatorial library --- library design --- screening --- mutagenesis --- prolyl-hydroxyproline (Pro-Hyp) --- hydroxyprolyl-glycine (Hyp-Gly) --- collagen peptide --- fibroblasts --- fetal bovine serum (FBS) --- AMD --- CNV --- VEGFR1 --- multimeric peptides --- oral delivery --- colorectal cancer --- cancer stem cells --- chemoprevention --- bioactive peptide --- lunasin --- ACE-inhibitory activity --- whey peptides --- molecular docking --- hypertension --- antibiotic resistance --- cystic fibrosis --- cryptides --- anti-biofilm peptides --- synergistic effects --- antihypertensive peptides --- functional food --- food-derived --- fermentation --- Chlorella sorokiniana --- in silico --- BIOPEP-UWM database --- proteomics --- bioactive peptides --- nano liquid chromatography tandem mass spectrometry (nanoLC-nanoESI MS/MS) --- apolipoprotein E --- amyloid fibrils --- Alzheimer's disease --- Αβ oligomer --- amyloid --- Aβ peptide --- glioma --- platelets --- antiproliferative assay --- conjugation --- docetaxel --- doxorubicin --- extra domain B --- fibronectin --- Fmoc/tBu --- peptide-drug conjugate --- prostate cancer --- solid-phase synthesis --- targeting --- acrylamide --- enteric nervous system --- galanin --- pig --- stomach --- formyl peptide receptors --- ligands --- diseases --- polymicrobial biofilms --- intragenic antimicrobial peptide --- Hs02 --- Pseudomonas aeruginosa --- Staphylococcus aureus --- osteostatin --- arthritis --- inflammation --- immune response --- cartilage destruction --- bone erosion --- collagen --- hydrolysis --- enzyme --- molecular weight --- sheepskin --- NF-κB --- dry-cured pork ham --- angiotensin I converting enzyme --- endothelial dysfunction --- molecular blind docking --- Lactoferricin B (Lfcin B) --- Histatin-5 --- antimicrobial peptides (AMPs) --- antifungal activity --- proteome microarray --- synergy --- temporin --- MRSA --- antimicrobial peptide --- human keratinocytes --- pseudin-2 --- antisepsis, peptide antibiotics --- neurotensin --- asthma --- T cells --- In situ tetramer staining --- MHC tetramer --- antigen-specific --- confocal microscopy --- fresh tissue --- velvet antler --- alcalase hydrolysate --- antioxidant peptide --- protection ability --- oxidative stress --- Crassostrea angulata --- pidotimod --- CXCR3 --- monocyte --- migration --- PI3K/Akt pathway --- T cell --- immunomodulant --- host defense peptides --- membrane activity --- copper --- piscidins --- Clostridioides difficile --- prolactin-releasing peptide --- GPR10 --- RF-amide peptides --- food intake regulation --- energy expenditure --- neuroprotection --- signaling --- gender differences --- dyslipidemia --- obesity --- hyperglycemia --- pulmonary emphysema --- endothelial progenitor cells --- angiogenic precursor cells --- pegylated glucagon-like peptide 1 --- and endothelial regeneration --- miiuy croaker (Miichthys miiuy) --- swim bladder --- FPYLRH --- antioxidant activity --- cytoprotective effect --- antimicrobial peptides --- antimicrobial resistance --- AMP identification and design --- biosynthesis --- mode of action --- physico-chemical properties --- therapeutic potential --- insects --- Cecropins --- Cec-analogs --- MDR infectious diseases --- airway inflammation --- non-atopic asthma --- hybrid peptide --- pro-inflammatory cytokines --- sPLA2 --- MDA --- database --- proteolysis --- SMILES code --- foods --- nutrition --- chronic diseases --- nutraceuticals --- peptide vaccine --- immune checkpoint inhibitor --- humanized mouse --- cancer antigen --- immune suppression --- vasoactive intestinal peptide --- VPAC1 receptor --- VPAC2 receptor --- rheumatic diseases --- inflammatory bowel disease --- central nervous system diseases --- type 1 diabetes --- Sjögren's syndrome --- biomarkers --- human antimicrobial peptides --- defensins --- cathelicidins --- anti-inflammatory --- pro-inflammatory --- peptide --- combinatorial library --- library design --- screening --- mutagenesis --- prolyl-hydroxyproline (Pro-Hyp) --- hydroxyprolyl-glycine (Hyp-Gly) --- collagen peptide --- fibroblasts --- fetal bovine serum (FBS) --- AMD --- CNV --- VEGFR1 --- multimeric peptides --- oral delivery --- colorectal cancer --- cancer stem cells --- chemoprevention --- bioactive peptide --- lunasin --- ACE-inhibitory activity --- whey peptides --- molecular docking --- hypertension --- antibiotic resistance --- cystic fibrosis --- cryptides --- anti-biofilm peptides --- synergistic effects